Everence Capital Management Inc. Boosts Stake in Humana Inc. (NYSE:HUM)

Everence Capital Management Inc. increased its position in shares of Humana Inc. (NYSE:HUM) by 57.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,530 shares of the insurance provider’s stock after buying an additional 2,020 shares during the quarter. Everence Capital Management Inc.’s holdings in Humana were worth $1,403,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in HUM. Moors & Cabot Inc. increased its holdings in shares of Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. OLD National Bancorp IN grew its position in Humana by 1.8% during the 3rd quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after purchasing an additional 45 shares during the last quarter. Your Advocates Ltd. LLP increased its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. Brooklyn Investment Group raised its holdings in shares of Humana by 6.7% in the third quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after buying an additional 46 shares during the last quarter. Finally, Demars Financial Group LLC boosted its stake in shares of Humana by 2.7% during the third quarter. Demars Financial Group LLC now owns 1,950 shares of the insurance provider’s stock worth $618,000 after buying an additional 52 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $262.47 on Friday. The company has a 50-day moving average of $272.56 and a two-hundred day moving average of $314.60. The stock has a market cap of $31.60 billion, a P/E ratio of 23.25, a PEG ratio of 2.12 and a beta of 0.53. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $471.37. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts predict that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Analyst Ratings Changes

HUM has been the subject of several analyst reports. Stephens reaffirmed an “equal weight” rating and set a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. Royal Bank of Canada cut their price target on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. KeyCorp assumed coverage on shares of Humana in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler downgraded shares of Humana from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $300.50.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.29% of the stock is currently owned by corporate insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.